1. The Food and Drug Administration (FDA) accepted BioXcel Therapeutics’ supplemental New Drug Application (sNDA) for at-home use of dexmedetomidine, but has not approved the use.
2. The SERENITY III phase 3 trial enrolled 452 participants; registry results report no efficacy or safety findings.
Evidence Rating Level: 2 (Good)
2MM Brief: BioXcel Therapeutics reported that the FDA accepted its sNDA seeking at-home use of IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. Acceptance initiates regulatory review; it is not an approval. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026. IGALMI is currently described by the company as a prescription medicine administered under the supervision of a health care provider for this indication. The company’s application concerns use in the at-home, or outpatient, setting, for which the source states there is currently no FDA-approved treatment option. The supporting registry entry describes SERENITY III (NCT05658510) as a phase 3 study sponsored by BioXcel Therapeutics, with enrollment of 452 and a completed status. The registry lists the primary outcome as Part 1 change from baseline in the Positive and Negative Syndrome Scale – Excited (PEC) total score. However, the available registry entry provides design information only and does not report efficacy estimates, confidence intervals, P values, follow-up duration, or safety results. The company’s materials state that the safety and efficacy of the investigational at-home use have not been established. They also state that IGALMI’s safety and effectiveness have not been studied beyond 24 hours from the first dose and list sleepiness or drowsiness, oral prickling or numbness, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing among the most common side effects in clinical studies. The regulatory announcement has not been peer reviewed, and the application remains under FDA review. These materials establish a regulatory milestone and identify a completed supporting trial, but they do not establish whether at-home dexmedetomidine is effective or safe for this use; the FDA’s review and reported clinical results will be needed to clarify its status.
© 2026 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine




